Aldeyra Therapeutics (NASDAQ:ALDX) Receives “Neutral” Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Aldeyra Therapeutics (NASDAQ:ALDX) in a research note issued to investors on Wednesday morning, Marketbeat reports. They currently have a $2.00 target price on the biotechnology company’s stock, down from their prior target price of $10.00.

Separately, BTIG Research restated a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aldeyra Therapeutics has a consensus rating of “Hold” and an average target price of $5.50.

Aldeyra Therapeutics Price Performance

Shares of Aldeyra Therapeutics stock opened at $1.42 on Wednesday. The company has a market capitalization of $85.46 million, a P/E ratio of -2.49 and a beta of 0.97. The business has a 50-day moving average of $4.87 and a two-hundred day moving average of $5.05. Aldeyra Therapeutics has a 1 year low of $1.07 and a 1 year high of $6.87.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings data on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. On average, equities analysts anticipate that Aldeyra Therapeutics will post -0.92 EPS for the current fiscal year.

Institutional Trading of Aldeyra Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Invesco Ltd. lifted its holdings in shares of Aldeyra Therapeutics by 22.0% in the fourth quarter. Invesco Ltd. now owns 163,087 shares of the biotechnology company’s stock valued at $845,000 after purchasing an additional 29,382 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Aldeyra Therapeutics by 22.5% during the fourth quarter. XTX Topco Ltd now owns 42,227 shares of the biotechnology company’s stock worth $219,000 after buying an additional 7,761 shares in the last quarter. Caption Management LLC acquired a new stake in Aldeyra Therapeutics in the 4th quarter valued at approximately $181,000. 683 Capital Management LLC raised its position in Aldeyra Therapeutics by 86.6% in the 4th quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock valued at $7,925,000 after buying an additional 710,000 shares during the last quarter. Finally, ACT Capital Management LLC bought a new stake in Aldeyra Therapeutics in the 4th quarter valued at approximately $212,000. Institutional investors and hedge funds own 59.71% of the company’s stock.

Trending Headlines about Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Neutral Sentiment: Short‑interest data published for mid‑March appears malformed (reports list 0 shares and NaN changes with a 0.0 days‑to‑cover). The numbers as reported are not actionable without corrected filings and should be treated as uncertain.
• Neutral Sentiment: HC Wainwright reaffirmed a “neutral” rating but cut its price target sharply to $2.00 from $10.00, signaling analysts are materially lowering their valuation assumptions for reproxalap while not taking a fully negative stance. HC Wainwright rating/price target note
• Negative Sentiment: The U.S. FDA issued a third Complete Response Letter for Aldeyra’s reproxalap NDA, citing insufficient efficacy for the treatment of dry‑eye disease — a setback that triggered a sharp selloff across multiple sessions and is the primary driver of the stock’s recent collapse. US FDA declines to approve Aldeyra’s drug
• Negative Sentiment: Coverage and headlines from multiple outlets highlight the third FDA rejection and the resulting market reaction (large intraday drops and headlines noting a 68–71% decline), reinforcing negative investor sentiment and pressuring liquidity. ALDX Crashes 71% as FDA Issues Third CRL
• Negative Sentiment: Several plaintiff and securities‑litigation firms (Levi & Korsinsky, Block & Leviton, Johnson Fistel and others) have launched or publicized investigations into Aldeyra and solicited shareholders — increasing legal risk, potential liability and uncertainty around management disclosures. ALDX Investor Alert: Securities Fraud Lawsuit
• Negative Sentiment: Unusual options activity: a large block of put purchases (reported ~31,566 puts) indicates traders were positioning for a steep decline, which likely amplified downward pressure on the stock during the FDA news.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.